NCT05433207 - Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis | Biotech Hunter

Enrollment

1,000

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG

Eldecalcitol soft capsules

0.75 μg orally once a day during the intensive monitoring period. (The dose can be appropriately reduced to 0.5 μg according to symptoms, once a day.)

Trial Locations (1)

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing